GlassScriptPhysician profile
Paula J Griffing
NPI 1578842027
$891.62
in general payments reported to CMS, 2019-2025
25 companies · $47.18 in 2025
The $47.18 reported for 2025 was less than what a typical Pediatrics (Nurse Practitioner) provider received nationally (typical 2025 total: $93.49).
See the full distribution for Pediatrics (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $298 · 2022: $168 · 2023: $129 · 2024: $249 · 2025: $47.18.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $425.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $425.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $120.96 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $78.14 | 2022-2025 | Breztri |
| Avanir Pharmaceuticals, INC. | $72.28 | 2022 | |
| Novartis Pharmaceuticals Corporation | $68.51 | 2021-2023 | |
| Otsuka America Pharmaceutical, INC. | $59.79 | 2023-2024 | Rexulti |
| Esperion Therapeutics, INC. | $56.34 | 2022-2024 | Nexletol |
| Janssen Pharmaceuticals, INC | $54.87 | 2021 | |
| Glaxosmithkline, LLC. | $44.36 | 2021 | |
| Exact Sciences Corporation | $34.31 | 2023-2024 | Cologuard Collection Kit |
| Lundbeck LLC | $33.02 | 2024 | Rexulti |
| Kowa Pharmaceuticals America, INC. | $28.16 | 2021 | |
| Phathom Pharmaceuticals, INC. | $27.84 | 2024 | Voquezna |
| Merck Sharp & Dohme LLC | $24.24 | 2024 | Verquvo |
| Amarin Pharma, INC. | $19.63 | 2021 | |
| Axsome Therapeutics, INC. | $19.33 | 2023 | Auvelity |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $19.19 | 2023 | Quviviq |
| Redhill Biopharma INC. | $19.14 | 2021 | |
| Amgen INC. | $17.08 | 2024 | Repatha, Otezla |
| Philips North America LLC | $16.26 | 2022 | |
| Xeris Pharmaceuticals, INC. | $14.91 | 2025 | Keveyis |
| Takeda Pharmaceuticals U.S.A., INC. | $14.66 | 2023 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $13.25 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.37 | 2021 | |
| Lilly USA, LLC | $12.19 | 2022 | |
| Genentech USA, INC. | $10.79 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paula Griffing listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.